教授

何志颖

发布时间:2019-05-08  



姓    名:何志颖

行政职务:同济大学附属东方医院再生医学研究所执行所长

                 课题组长

学    位:博士

导师情况:博士生导师

研究领域:干细胞与再生医学、细胞成药

研究方向:

1、干细胞肝向分化、肝向重编程及肝干细胞生物学

2、干细胞基础与转化医学研究

3、肝细胞移植和人源化肝脏

4、肝衰竭、肝硬化等肝病的细胞治疗

5、肝细胞衰老与肝癌发生、肝癌衰老诱导治疗及血管浸润与早期肝癌转移的机制研究


E-mail: zyhe@tongji.edu.cn; zhiyinghe2002@163.com

联系电话:021-38804518-22241

通讯地址:同济大学附属东方医院再生医学研究所

                 http://easthospital.cn/deri

 

个人简历:

       同济大学转化医学高等研究院研究员、博士生导师,同济大学附属东方医院再生医学研究所特聘研究员、执行所长、课题组长,上海干细胞转化医学工程技术研究中心主任,同济大学东方临床医学院生物技术教研室主任,上海赛傲生物技术股份有限公司首席科学家。兼任新疆医科大学、南京医科大学、锦州医科大学研究生导师。获国家重点研发计划项目首席科学家、上海市优秀学术技术带头人、上海市五一劳动奖章、上海市浦江人才、军队优秀专业技术人才、同济大学中青年科技领军人才等。有中国细胞生物学学会细胞治疗研究与应用分会秘书长、中国解剖学会医学发育生物学分会副主任委员、中国整形美容协会干细胞研究与应用分会副会长、中华医学会医学细胞生物学分会委员、中国细胞生物学学会细胞工程与转基因生物分会委员、中国细胞生物学学会青年工作委员会委员、中国整形美容协会干细胞研究与应用分会青年工作委员会主任委员、中国抗衰老促进会专家委员会委员、全国卫生产业企业管理协会细胞治疗产业与临床研究分会常务委员、Cell Transplantation编委、同济大学学报(医学版)编委、医学参考报干细胞与再生医学频道常务编委等学术任职。

1999年毕业于第二军医大学临床医学专业,获医学学士学位。2000年至2006年毕业于第二军医大学细胞生物学专业,获理学博士学位。2006年至2009年中国科学院上海生化细胞所博士后。2014-2016年美国宾夕法尼亚大学 Perelman 医学院访问教授。2011-2017年任第二军医大学细胞生物学教研室副教授、副主任。

热忱欢迎报考本课题组研究生和博士后,提供优越的课题开展条件(再生所拥有处于国内外先进水平的技术平台和仪器设备,从基础到转化到临床的课题及充足的课题经费),提供优越的个人待遇和发展空间。个人待遇:学校政策最高待遇+课题组研究生补助+再生所奖学金+发表文章奖励(博士后基金申请奖励)等;个人发展空间:东方医院三院建设打造沪上最大公立医院,为医院与再生所科研发展带来的个人空间和工作岗位;推荐科研院所或企业单位。


研究成果:

立足于国内研究基础和团队合作,以干细胞与肝脏再生为研究方向,开展肝细胞移植的基础和应用研究,致力于肝脏疾病的细胞治疗。在肝向谱系重编程、肝干细胞生物学和干细胞肝向分化、肝细胞衰老及衰老抑制、肝脏疾病的细胞和基因治疗及肝癌的发生发展机制等研究方面取得系列重要进展。

主持国家重点研发计划干细胞及转化研究重点专项(首席科学家)、国家自然科学基金(6项)、国家重点研发计划发育编程及其代谢调节重点专项PI、上海市科委重大课题、江西省自然基金重点项目等30余项课题,累计经费13255万元。发表论文92篇,其中SCI论文63篇,总影响因子521。以第一作者或通讯作者(含共同)发表SCI论文37篇,总影响因子3304篇影响因子大于20。申请专利15项,其中8项已授权,国际PCT专利1项。参加专著和国家统编教材编写9部,承担教学课题和学生创新指导课题11项。研究成果被评为中国科学十大进展、细胞出版社中国年度论文、上海市优秀发明金奖、上海医学科技奖等。研发和推动多个干细胞治疗新药临床注册研究或干细胞临床备案研究。

在肝向谱系重编程获得非供体肝细胞来源、干细胞肝向分化、肝细胞移植与功能评价、肝细胞衰老与肝癌发生等研究方面取得了系列标志性成果。研究成果先后发表在Nature, Cell Stem Cell, Gastroenterology, Hepatology, Cell Research, NPJ Regenerative MedicineBiomaterials, American Journal of Pathology, Cell Death & Disease,  Frontiers of Medicine , Cell Oncol (Dordr), Frontiers in Cell and Developmental Biology等国际期刊


  • 开展谱系重编程研究,利用国内研究基础,在肝向谱系重编程研究方面取得原创性重大进展。首次证明通过转染肝脏转录因子Gata4, Hnf1αFoxa3可以将小鼠成纤维细胞直接诱导为有功能的肝细胞(Nature 2011第二作者),该项工作被评为2011年度中国科学十大进展之一;首次证明了通过转染肝脏转录因子Hnf1βFoxa3可以实现小鼠成纤维细胞向肝干细胞分化的重编程,诱导的肝干细胞可以在体内、外分化为成熟的肝细胞和胆管上皮细胞,《SciBX》将这一成果作为精选亮点(distillery)报道(Cell Stem Cell 2013,共同第一;Int J Biochem Cell Biol2016);首次证明通过转染肝脏转录因子FOXA3HNF1AHNF4A可以将人成纤维细胞谱系重编程为有功能的肝细胞,获得的诱导型人肝细胞在生物医学研究和制药工业上具有极大应用价值(Cell Stem Cell 2014,共同第一),该项工作入选美国细胞出版社“2014中国年度论文

  • 开展干细胞的肝向分化研究,利用胚胎、肝脏等来源的多种干细胞进行了系统的肝向分化研究,建立了成熟的干细胞肝向分化和功能检测的技术体系(The International Journal of Biochemistry & Cell Biology 2012,第一作者;Journal of Cellular Biochemistry 2011,共同第一);发现胚胎干细胞肝向分化的c-Kit-EpCAM+细胞中富集了具有肝脏再殖能力和自我更新能力的肝前体细胞,该成果被Connexon Creative公司ESC iPSC News作为TOP STORY推荐(Gastroenterology 2010,通讯作者);发现经胆管化可分别实现将小鼠或人原代肝细胞诱导为胆管样肝前体细胞,诱导的肝前体细胞可在体内外分化为成熟的肝细胞,可实现肝细胞的规模化培养(Cell Research 2017,共同第一;Cell Research 2019a,共同通讯)。发现人ES细胞分化的肝祖细胞可作为HCV感染研究的理想细胞模型(Hepatology2017);发现胆管树干细胞(BTSCs)向肝细胞成熟分化的调控机制,揭示了潜在的调节肝细胞分化成熟的转录因子-miRNA-靶基因调控网络,并发现PI3K/AKT信号通路在BTSCs肝向成熟分化中的关键作用(Frontiers in Cell and Developmental Biology2021a)。

  • 开展了肝细胞的衰老机制及衰老逆转的研究,发现连续移植的肝细胞具有不衰老的特性,衰老的肝细胞经倍体转换其衰老特性可以逆转(Hepatology 2014,共同通讯)。在全基因组水平上揭示了转录因子Foxa2GATA4在定性内胚层细胞中的结合图谱,以及GATA4Foxa2对靶基因的共调控在定型内胚层发育及其向肝细胞分化的过程中的先锋因子作用(Journal of Molecular Cell Biology2012);发现I型酪氨酸血症中铁离子的蓄积在肝损伤中的作用及其发生的分子机制,揭示了铁离子代谢和酪氨酸代谢之间的相互作用(Journal of Hepatology2016);发现骨髓间充质干细胞移植可以缓解牛磺胆酸诱导的大鼠重症急性胰腺炎(Stem Cells International 2016,共同第一)。

  • 开展肝细胞移植策略的基础与应用研究,建立了同时将多个基因导入成体肝实质细胞的技术体系(Hepatology, 2008);建立了人源化肝脏嵌合体小鼠制备的技术方案,建立了人肝细胞分离、移植及功能评价的技术体系(American Journal of Pathology 2010,第一作者;Sci China Life Sci 2011,通讯作者);发现肝细胞经FoxM1基因修饰后可显著增强其再殖肝脏的能力,发现衰老肝细胞分泌IGF2是促进移植肝细胞再殖受体肝脏的机制,IGF2具有促进移植细胞再殖肝脏的应用前景(Cell Death Disease 2014,通讯作者;Cell Death Disease 2018a,通讯作者);发现通过构建基于透明质酸的补片移植技术,可以实现胆管树干细胞biliary tree stem cells, BTSCs)向肝脏等实体脏器的高效移植,定植肝脏的BTSCs可以在3周内成熟分化为肝细胞(NPJ Regenerative Medicine 2023Biomaterials 2022,Biomaterials 2021,通讯作者);建立了细胞移植后活体示踪的技术方案,应用肝细胞体内功能评价的动物模型(获2020年度上海医学科技奖二等奖),通过三维(3D)示踪技术对植入肝脏的肝细胞进行实时定位与定量,从而对移植肝衰竭小鼠模型的肝细胞实现了体内命运示踪(Frontiers in Cell and Developmental Biology 2021b,通讯作者)。

  • 开展肝癌细胞的重编程研究,发现通过转染肝脏转录因子FOXA3HNF1AHNF4A可以将人肝癌细胞诱导为肝细胞样细胞,为肝癌治疗提供了新的治疗策略(Cell Research 2019b,共同第一);开展肝细胞衰老与肝癌发生机制的研究,发现肝细胞的损伤程度决定着肝细胞走向衰老或发生肝癌的命运转变,损失程度较重时通过诱导肝细胞衰老并激活免疫监控清除衰老细胞,从而降低了肝癌的发生率(Cell Oncol (Dordr). 2022;Cell Death Disease 2018b,通讯作者;Oncotarget 2017,通讯作者);发现微管解聚蛋白-1(STMN1)与肝癌的转移密切相关,并证实STMN1可作为MVI的诊断和风险分级标志物(Cell Death Disease 2022,通讯作者);发现miR-17通过抑制Smad3的表达促进了肝癌的发生,miR-17可作为肝癌诊断和治疗的潜在靶点(Cell Death Disease 2019,通讯作者);发现肝癌中TCTP mRNA通过扮演海绵蛋白角色维持TCTP蛋白在肝癌细胞中的内稳态平衡(Cell Death Disease 2020,共同通讯);发现双特异性磷酸酶16DUSP16)通过调控p53Rb通路、保护肿瘤细胞免于衰老从而促进肿瘤细胞的生长(FEBS J2015);应用RNA-seq技术对胃癌的转录组特征进行了分析(Tumour Biol2014);建立了小鼠胚胎干细胞和肿瘤细胞的细胞融合模型,分析了肝癌细胞重编程后的动态表观遗传调控(The Journal of Biological Chemistry2010);建立了基于MRI引导、可应用于胰腺癌靶向治疗的MSLN多功能纳米载药脂质体的制备方案(International Journal of Nanomedicine 2012,共同第一)。


代表性论文:

1. Yu B#, He ZY#, You P, Han QW, Xiang D, Chen F, Wang MJ, Liu CC, Lin XW, Borjigin U, Zi XY, Li JX, Zhu HY, Li WL, Han CS, Wangensteen KJ, Shi YF, Hui LJ, Wang X, Hu YP. Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors. Cell Stem Cell 2013; 13(3):328-340. (#共同一作,IF: 22.151).

2. Huang PY#, Zhang LD#, Gao YM#, He ZY#, Yao D, Wu ZT, Cen J, Chen XT, Liu CC, Hu YP, Lai DM, Hu ZL, Chen L, Zhang Y, Cheng X, Ma XJ, Pan GY, Wang X, Hui LJ. Direct reprogramming of human fibroblasts to functional and expandable hepatocyte cells. Cell Stem Cell 2014; 14(3):370-84. (#共同一作,IF: 22.268). 入选美国细胞出版社“2014中国年度论文/机构”.

3. Huang PY, He ZY, Ji SY, Sun HW, Xiang D, Liu CC, Hu YP, Wang X, Hui LJ. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475: 386-389. (IF: 36.280). 入选科技部“2011年中国十大科学进展.

4. Cheng Z#, He ZY#, Cai YC#, Zhang C#, Fu GB, Li HY, Sun W, Liu CC, Cui XL, Ning BF, Xiang DM, Zhou TF, Li XF, Xie WF, Wang HY*, Ding J*.  Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors. Cell Research 2019; 29(2):124-135.  (#共同一作,IF: 20.51).

5. Fu GB#, Zhou X#, Zeng M#, Huang WJ#, Wu HP#, Liu CC, Wu H, Weng J, Zhang HD, Cai YC, Ashton C, Ding M, Tang D, Zhang BH, Gao Y, Yu WF, Zhai B*, He ZY*, Wang HY*, Yan HY*. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells for the study of hepatotropic pathogen. Cell Research 2019; 29(1):8-22. (*通讯作者,IF: 20.51).

6. Wu H#, Zhou X#, Fu GB#, He ZY#, Wu HP#, Zeng M, Zhang HL, You P, Ashton C, Wang X, Wang HY, Yan HX. Reversible transition between hepatocytes and liver progenitors for in vitro hepatocyte expansion. Cell Research 2017; 27(5):709-712. (#共同一作,IF: 15.61).

7. Li FM, Liu PY, Liu CC, Xiang D, Deng L, Li WL, Wangensteen KJ, Song JG, Ma Y, Hui LJ, Wei LX, Li LS, Ding XY, Hu YP, He ZY*, Wang X*. Hepatoblast-like progenitor cells derived from embryonic stem cells can repopulate livers of mice. Gastroenterology 2010, 139(6): 2158-2169. e8. (*通讯作者,IF: 12.032)

8. Wang MJ, Chen F, Li JX, Liu CC, ZhangHB, Xia Y, Yu B, You P, Xiang D, Lu L, Yao H, Borjigin U, Yang GS, Wangensteen LJ, He ZY*, Wang X*, Hu YP*. Reversal of hepatocytes senescence after continuous in vivo cell proliferation. Hepatology 2014; 60(1): 349-61. (*通讯作者,IF: 11.055)

9.  Zhang WC#, Wang XC#, Giacomo Lanzoni, Eliane Wauthier, Sean Simpson, Jennifer Ashley Ezzel, Amanda Allen, Carolyn Suitt, Joshua Krolik, Alexander Jhirad, Juan Dominguez-Bendala, Vincenzo Cardinale, Domenico Alvaro, Diletta Overi, Eugenio Gaudio, Kyle Mathews, Christopher Adin*, Praveen Sethupathy*, Jorge Piedrahita*, Zhiying He*, Guido Carpino*, and Lola M. Reid*. NPJ Regenerative Medicine. 2023 published on line. (*通讯作者, IF: 14.404, 2022)

10. Zhang WC, Wauthier E, Lanzoni G, Hani H, Yi XW, Overi D, Shi L, Simpson S, Allen A, Suitt C, Ezzell JA, Alvaro D, Cardinale V, Gaudio E, Carpino G, Prestwich G, Dominguez-Bendala J, Gerber D, Matthews K, Piedrahita J, Adin C, Sethupathy P*, He ZY*,  Reid LM*. Patch Grafting of Stem/Progenitor Organoids: Strategies for Cell Therapies for Solid Organs and exemplified in Liver and Pancreas. Biomaterials 2022; 288: 121647. doi: 10.1016/j.biomaterials.. (*Senior authors, IF: 15.304)

11.Zhang WC, Lanzoni G, Hani H, Diletta O, Cardinale V, Simpson S, Pitman W, Allen A, Yi XW, Wang XC, Gerber D, Prestwich G, Lozoya O, Gaudio E, Alvaro D, Tokaz D, Dominguez-Bendala J, Adin C, Piedrahita J, Matthews K, Sethupathy P, Carpino G*, He ZY*, Wauthier E*, Reid LM*. Patch Grafting, Strategies for Transplantation of Organoids into Solid Organs such as Liver. Biomaterials 2021 Oct; 277:121067. doi: 10.1016/j.biomaterials. 2021.121067. Epub 2021 Aug 25. (*Senior authors, IF: 12.479)

12. Cai YC#, Fu Y#, Liu CC#, Wang XC#, You P, Li XH, Song YX, Mu XN, Jiang D, Yang Y, Gu YY, Zhang HB*, He ZY*. Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma. Cell Death & Disease 2022. (*通讯作者,IF: 8.469).

13. Liu P, Wang XJ, Pan LL, Han B, He ZY*. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis. Frontiers in Immunology 2022; 901784. doi: 10.3389/fmmu.2022.901784.  (*通讯作者, IF: 7.561)

14. Chen WJ, Zhang WC, Chen MM, Yang C, Fang T, Wang HF, Reid LM, He ZY*. Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumors. Cell Oncol (Dordr). 2022 Sep 10. doi: 10.1007/s13402-022-00714-4. (*通讯作者, IF: 7.051)

15.Yong Yang#, Wencheng Zhang#, Jingxian Yang, Xicheng Wang, Yangyang Cui, Haimeng Song, Weiping Li, Wei Li, Le Wu, Yao Du, Zhiying He*, Jun Shi*, Jiangnan Zhang*. A passage-dependent network for estimating the in vitro senescence of mesenchymal stromal/stem cells using microarray, bulk and single cell RNA sequencing. Frontiers in Cell and Developmental Biology. 2023. DOI: 10.3389/fcell.2023.998666. (*通讯作者,IF: 6.081, 2022)

16. Du Y, Zhang WC, Qiu H, Xiao CJ, Shi J, Reid LM, He ZY*. Mouse Models of Liver Parenchyma Injuries and Regeneration. Frontiers in Cell and Developmental Biology 2022; 10.3389/fcell.2022.903740. (*通讯作者,IF: 6.684, 2020)

17. Liang XT, Zhang YL, Lin F, Li MM, Li X, Chen Y, Liu J, Meng QS, Ma XX, Wang EH, Wei L, He ZY, Fan HM, Zhou XH, Ding Y, Liu ZM. Direct administration of mesenchymal stem cell-derived mitochondria improves cardiac function after infarction via ameliorating endothelial senescence. Bioengineering & Translational Medicine 2022. First published: 29 June 2022. (IF: 10.684, 2021)

18. Zhang WC, Lou YR, Zhou JJ, He ZY. Editorial: Stem Cells in Tissue Homeostasis and Disease. Frontiers in Cell and Developmental Biology 2022; 10: 876060. doi: 10.3389/fcell.2022.876060.

19. Liu J, Liang X, Li M, Lin F, Ma X, Xin Y, Meng Q, Zhuang R, Zhang Q, Han W, He Z, Zhou X, Liu Z. Intramyocardial Injected Human Umbilical Cord-Derived Mesenchymal Stem Cells (Hucmscs) Contribute to the Recovery of Cardiac Function and the Migration of CD4+ T Cells into the Infarcted Heart via CCL5/CCR5 Signaling. Stem Cell Research & Therapy 2022; 13:247https://doi.org/10.1186/s13287-022-02914-z. (IF: 6.832)

20. Lu FF#, Pan X#, Zhang WC#, Su X, Gu YY, Qiu H, Shen SW, Liu CC, Liu W, Zhan ZZ, Liu ZM*, He ZY*. A Three-dimensional Imaging Method for the Quantification and Localization of Dynamic Cell Tracking Post-transplantation. Frontiers in Cell and Developmental Biology 2021; 9: 698795. doi: 10.3389/fcell.2021.698795. (*通讯作者,IF: 6.684) 

21.Wang SS#, Jiang K#, Lu YL,Liao LJ, He ZY*, He WZ*. Translational Attenuation Mechanism of ErmB Induction by Erythromycin Is Dependent on Two Leader Peptides. Frontiers in Microbiology 2021; 12: 609711. doi: 10.3389/fmicb.2021.690744. (*通讯作者,IF: 5.64)

22. Wang XC#, Zhang WC#, Yang Y, Wang JS, Qiu H, Liao LJ, Oikawa T, Wauthier E, Sethupathy P, Reid LM, Liu ZM*, He ZY*. A MicroRNA-Based Network Provides Potential Predictive Signatures and Reveals the Crucial Role of PI3K/AKT Signaling for Hepatic Lineage Maturation.  Frontiers in Cell and Developmental Biology   2021, Front. Cell Dev. Biol. 9: 670059. doi: 10.3389/fcell.2021.670059. (*通讯作者,IF: 6.684). 

23. Lu ZF#*, Li XH#, Xu YF, Chen MM, Chen W, Chen T, Tang QH*, He ZY*. microRNA-17 functions as an oncogene by down-regulating Smad3 expression in hepatocellular carcinoma. Cell Death & Disease 2019; 10(10):723. doi: 10.1038/s41419-019-1960-z. (*通讯作者,IF: 6.30)

24. Liu W#, Liu Q#, Zhang BL, Lin ZB, Li X, Yang XS, Pu M, Zou RZ, Wang XC, He ZY*, Wang F*, Dou KF*. The mRNA of TCTP functions as a sponge to maintain homeostasis of TCTP protein levels in hepatocellular carcinoma. Cell Death & Disease 2020; Accept. (*通讯作者,IF: 8.469)

25. Wang MJ#, Chen F#, Liu QG#, Liu CC, Yao H, Yu B, Zhang HB, Yan HX, Ye YB, Chen T, Wangensteen KJ, Wang X, Hu YP*, He ZY*. Insulin-like growth factor 2 is a key mitogen driving liver repopulation in mice. Cell Death & Disease 2018; 9:26, DOI 10.1038/s41419-017-0186-1. (*通讯作者,IF: 5.959)

26. Wang C#, Chen WJ#, You P#, Wu YF#, Zheng SY, Liu CC, Xiang DWang MJ#, Cai YC, Zhao QH, Borjigin U, Liu W, Xiong WJ, Wangensteen KJ, Wang X, Liu ZM*, He ZY*. The extent of liver injury determines hepatocyte fate toward senescence or cancer. Cell Death & Disease 2018; 9: 575, DOI 10.1038/s41419-018-0622-x. (*通讯作者,IF: 5.959).

27. He ZY, Zhang HB, Zhang X, Xie DF, Chen YX, Wangensteen KJ, Ekker SC, Firpo M, Liu CC, Xiang D, Zi XY, Hui LJ, Yang GS, Ding XY, Hu YP, Wang X. Liver Xeno-Repopulation with Human Hepatocytes in Fah-/-Rag2-/- Mice after Pharmacological Immunosuppression. American Journal of Pathology 2010; 177(3): 1311-9. (第一作者,IF: 5.224)

28. Xiang D, Liu CC, Wang MJ, Li JX, Chen F, Yao H, Yu B, Lu L, Borjigin U, Wangensteen KJ, He ZY*, Wang X*, Hu YP*. Non-viral FoxM1 gene delivery to hepatocytes enhances liver repopulation. Cell Death & Disease 2014; 5:e1252. doi: 10.1038/cddis.2014.230. (*通讯作者,IF: 5.014)

29. Liu P#, Tango QH#, Chen MM, Chen WJ, Lu YL, Liu ZM*, He ZY*. Hepatocellular senescence: immunosurveillance and future senescence-induced therapy in hepatocellular carcinoma. Frontiers in Oncology 2020; doi: 10.3389/fonc.2020.589908. (*通讯作者,IF: 4.848)

30. Xiao MC#, Chen WJ#, Wang C, Wu YF, Zhu SW, Zeng CY, Cai YC, Liu CC, He ZY*.  Senescence and cell death in chronic liver injury: roles  and       

      mechanisms underlying hepatocarcinogenesis. Oncotarget 2017 Dec 22;9(9):8772-8784. (*通讯作者)

31. He ZY, Deng L, Li YF, Xiang D, Hu JK, Chen YX, Wang MJ, Chen F, Liu CC, Li WL, Zi XY, Wu X, Li GP, Wangensteen KJ, Hu YP, Wang X. Murine Embryonic Stem Cell-derived Hepatocytes Correct Metabolic Liver Disease after Serial Liver Repopulation. The International Journal of Biochemistry & Cell Biology 2012; 44(4): 648-58. (第一作者,IF: 4.152)

32. Li FM#, He ZY#, Li YF, Liu PY, Chen F, Wang MJ, Zhu HY, Ding XY, Wangensteen KJ, Hu YP, Wang X. Combined Activin A/LiCl/Noggin treatment improves production of mouse embryonic stem cell-derived definitive endoderm cells. Journal of Cellular Biochemistry 2011; 112(4): 1022-34. (#共同一作,IF: 2.868)

33. Deng L#, Ke X#, He Z#, Yang D, Gong H, Zhang Y, Jing X, Yao J, Chen J. A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer. International Journal of Nanomedicine 2012; 7: 5053-5065. (#共同一作,IF: 3.463)

34. Zhao H#, He ZY#, Huang DD, Gao J, Gong YF, Wu HY, Xu AF, Meng XJ, Li ZS. Infusion of bone marrow mesenchymal stem cells attenuates experimental severe acute pancreatitis in rats.  Stem Cells International  2016:7174319. Epub 2016 Sep 18. (#共同一作,IF: 3.687)

35. Su BL, Liu CC, Xiang D, Zhang HB, Yuan SM, Wang MJ, Chen F, Zhu HY, He ZY*, Wang X, Hu YP*. Xeno-liver repopulation of human hepatocyte in Fah-/-Nod/Scid mice. Sci China Life Sci 2011; 54(3): 1-8. (*通讯作者,IF: 2.024)

36. Becker JS, Sidoli S, Donahue G, Kaeding KE, McCarthy RL, He ZY, Lin S, Garcia BA, Zaret KS. Genomic and Proteomic Resolution of Structural Heterochromatin and its Restriction of Alternate Fate Genes. Molecular Cell 2017; 68, 1023-1037. (IF: 14.714)

37. Yan F, Wang Y, Zhang W, Chang M, He ZYXu J, Shang C, Chen T, Liu J, Wang X, Pei X, Wang Y. Human ES Cell-derived hepatoblasts are an optimal lineage stage for HCV infection. Hepatology 2017; 66(3): 717-735. (IF: 11.711)

38. Bao WD, Fan Y, Deng YZ, Long LY, Wang JJ, Guan DX, Qian ZY, An P, Feng YY, He ZY, Wang XF, Koeffler HP, Hu R, Wang J, Wang X, Wang F, Li JJ, Xie D. Iron Overload in Hereditary Tyrosinemia Type 1 Induces Liver Injury through the Sp1/Tfr2/Hepcidin Axis. J Hepatol; 65(1):137-45. (IF: 10.59)

39. Chen F, Yao H, Wang M, Yu B, Liu Q, Li J, He ZY, Hu YP. Suppressing Pitx2 inhibits proliferation and promotes differentiation of iHepSCs. Int J Biochem Cell Biol 2016; 80:154-162. (IF: 3.905)

40. Zhang H, Zheng H, Mu W, He ZY, Yang B, Ji Y, Hui L. DUSP16 ablation arrests cell cycle and induces cellular senescence. FEBS J 2015; 282(23): 4580-94. (IF: 4.237)

41. Zhang FG, He ZY, Wang Q. Transcriptome profiling of the cancer and normal tissues from gastric cancer patients by deep sequencing. Tumour Biol 2014; 35(8): 7423-7. (IF: 3.611)

42. Xu C, Lv X, Chen EZ, He ZY, Uyunbilig B, Li G, Ma Y, Hui L, Xie B, Gao Y, Ding X, Hu Y, Hu P, Han JD, Wang X. Genome-wide roles of Foxa2 in directing liver specification. Journal of Molecular Cell Biology 2012; 4: 420-422. (IF: 7.308)

43. Yao JY, Zhang L, Zhang X, He ZY, Ma Y, Hui LJ, Wang X, Hu YP. H3K27 Trimethylation is an Early Epigenetic Event of P16INK4a Silencing for Regaining Tumorigenesis in Fusion Reprogrammed Hepatoma Cells. The Journal of Biological Chemistry 2010; 285(24): 18828-37. (IF: 5.328)

44. Li XH#, Yang Y#, Liu W, Chen WJ, Hu KY, Wang WY, Wang C, Wu YF, Liu ZM*, He ZY*. Nanomaterials in liver regeneration: the prospect for application. Nano Life 2018; 8(4): 1841005. (*通讯作者)

45. Yang Y#, Li XH#, Liu W, Chen JW, Liu CC, Cai YC, Song YX, Tang QH, Zhang C*, He ZY*. Generation of hepatocyte-like cells by different strategies   for liver regeneration.  Nano Life 2018; 8(4): 1841004. (*通讯作者)

46. Fu YB, He ZY*, Zhang C*. Advances of Stem Cell Therapy to Treat Heart Failure. Nano Life 2019; 9(3): 1941002. * (*通讯作者)

Copyright© 2011-2015 生命科学与技术学院, All rights reserved

地址:上海市四平路1239号 电话:021-65981041 传真:65981041